Subject characteristics
| Surgery group (n=28) | Control group (n=28) | Group difference | |
|---|---|---|---|
| Age (y) at baseline examination: | |||
| Mean (SD) | 11.5 (3.5) | 10.3 (3.7) | NS1-150 |
| Range | 5–16 | 4–16 | |
| Age (y) at onset of epilepsy: | |||
| Mean (SD) | 5.6 (4.2) | 5.4 (4.3) | NS1-150 |
| Range | 0–15 | 0–15 | |
| IQ (mean (SD)) | 80.7 (16.8) | 84.2 (22.8) | NS1-150 |
| Range | 50–115 | 54–119 | |
| Sex (male/ female) | 14/14 | 18/10 | NS1-151 |
| Seizure type (SPS/CPS/SGS, drop attacks) | 2/17/9 | 1/22/5 | NS1-151 |
| Seizure frequency (seizures/month): | |||
| Median | 17.5 | 30.0 | NS1-152 |
| Seizure outcome | p<0.0011-151 | ||
| Seizure free | 21 (75%) | 4 (14%) | |
| Sign (⩾50%) reduction in seizure frequency | 5 (18%) | 6 (22%) | |
| Seizue frequency unchanged | 2 (7%) | 18 (64%) | |
| Baseline medication | NS1-151 | ||
| No medication | 1 | 1 | |
| Monotherapy | 3 | 8 | |
| Polytherapy | 24 | 19 | |
| Antiepileptic treatment | NS1-151 | ||
| Number of drugs increased | 2 | 5 | |
| Number of drugs reduced | 11 | 5 | |
| Number of drugs unchanged | 15 | 18 | |